WallStSmart

Anheuser Busch Inbev NV ADR (BUD)vsCVS Health Corp (CVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CVS Health Corp generates 574% more annual revenue ($399.83B vs $59.32B). BUD leads profitability with a 11.5% profit margin vs 0.4%. CVS appears more attractively valued with a PEG of 0.24. CVS earns a higher WallStSmart Score of 65/100 (C+).

BUD

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 6.5Value: 4.7Quality: 5.0

CVS

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 4.0Value: 7.3Quality: 5.0
Piotroski: 4/9Altman Z: 2.11
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BUDOvervalued (-12.7%)

Margin of Safety

-12.7%

Fair Value

$68.57

Current Price

$75.55

$6.98 premium

UndervaluedFair: $68.57Overvalued
CVSUndervalued (+77.4%)

Margin of Safety

+77.4%

Fair Value

$340.13

Current Price

$86.86

$253.27 discount

UndervaluedFair: $340.13Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BUD4 strengths · Avg: 8.8/10
EPS GrowthGrowth
63.3%10/10

Earnings expanding 63.3% YoY

Market CapQuality
$140.73B9/10

Large-cap with strong market position

Operating MarginProfitability
24.9%8/10

Strong operational efficiency at 24.9%

Free Cash FlowQuality
$9.89B8/10

Generating 9.9B in free cash flow

CVS5 strengths · Avg: 9.4/10
PEG RatioValuation
0.2410/10

Growing faster than its price suggests

Price/BookValuation
1.5x10/10

Reasonable price relative to book value

EPS GrowthGrowth
76.6%10/10

Earnings expanding 76.6% YoY

Market CapQuality
$105.21B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.61B8/10

Generating 2.6B in free cash flow

Areas to Watch

BUD3 concerns · Avg: 4.0/10
PEG RatioValuation
1.724/10

Expensive relative to growth rate

Price/BookValuation
10.1x4/10

Trading at 10.1x book value

Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

CVS4 concerns · Avg: 3.0/10
Return on EquityProfitability
2.3%3/10

ROE of 2.3% — below average capital efficiency

Profit MarginProfitability
0.4%3/10

0.4% margin — thin

Operating MarginProfitability
1.6%3/10

Operating margin of 1.6%

Debt/EquityHealth
1.243/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : BUD

The strongest argument for BUD centers on EPS Growth, Market Cap, Operating Margin.

Bull Case : CVS

The strongest argument for CVS centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.24 suggests the stock is reasonably priced for its growth.

Bear Case : BUD

The primary concerns for BUD are PEG Ratio, Price/Book, Revenue Growth.

Bear Case : CVS

The primary concerns for CVS are Return on Equity, Profit Margin, Operating Margin. A P/E of 59.1x leaves little room for execution misses. Thin 0.4% margins leave little buffer for downturns.

Key Dynamics to Monitor

BUD carries more volatility with a beta of 0.79 — expect wider price swings.

CVS is growing revenue faster at 8.4% — sustainability is the question.

BUD generates stronger free cash flow (9.9B), providing more financial flexibility.

Monitor BEVERAGES - BREWERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CVS scores higher overall (65/100 vs 61/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Anheuser Busch Inbev NV ADR

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.

CVS Health Corp

HEALTHCARE · HEALTHCARE PLANS · USA

CVS Health (previously CVS Corporation and CVS Caremark Corporation) is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands. The company's headquarters is in Woonsocket, Rhode Island.

Visit Website →

Want to dig deeper into these stocks?